u/deleted_my_history

nothing containing this is approved anywhere yet

Which endpoint — histological response, fibrosis improvement, or fat fraction?

This is the framing the board needs. It is a hepatic programme first.

Yes. Naming conventions in this corner are loose enough that the same word covers several different molecules.

Because it is not a peptide, it is not subject to the same degradation pathways, does not require the absorption enhancers used for oral peptides, and can be formulated as a conventional tablet.

Nothing containing this compound is approved anywhere.

Agreed, and the glucagon arm is exactly why the comparison threads do not work.

What does the notice actually say, in its own words?

Shipped from regional stock or from origin?

Is there a deadline on the notice?

the escalation is where most of the reported trouble sits

research-use-only material is not approved for human use

dual GLP-1 and glucagon agonist, and the glucagon arm is the story

the boards keep comparing it to injectables at matched doses, which is meaningless

Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.

Which phase 2 arm are you quoting, and at what week?

That is body weight change, not fat mass. The trials report the first and people quote it as the second.

the glucagon component is why the metabolic story reads differently

phase 2 data only, and people quote it like it is a label

What the glucagon arm is doing, as best anyone can say from public data.

GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.

Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.

That is body weight change, not fat mass. The trials report the first and people quote it as the second.

catalogue depth is not the same as catalogue quality

Net peptide content accounts for counterion, water and residual solvent.

This is the rule for anything unusual. Identity before anything else.

Confirmed the lead time in writing before ordering a made-to-order line. It was longer than the site suggested and entirely reasonable once explained.

dose escalation in the trials was slow for a reason

the same name covers several different molecules in this space

Same. Very thin independent data on this one, which should make everybody here more tentative than they are.

The nausea profile felt different rather than worse.

This is the sentence the rest of the board should read first. Phase 2 is not a label.

small trial, big effect, wide error bars

This is the sentence the rest of the board should read first.

devils_advocate_d is right about the escalation being the variable. It explains most of the difficult reports here.

How long has it been sitting, and at which stage?

dose escalation in the trials was slow for a reason

handling and storage vary enormously across this catalogue

the answer for Germany does not apply anywhere else

Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

Same. Very thin independent data on this one, which should make everybody here more tentative than they are.

not approved anywhere, which is the single most important fact in this board

Yes. Oral peptide with an absorption enhancer and oral small molecule are completely different propositions.